OPKO HEALTH INC.

A Phase 3, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis compared with Lucentis monotherapy every 4 weeks in patients with Exudative Age-Related Macular Degeneration (AMD)